Skip to main content
Fig. 3 | Biomarker Research

Fig. 3

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Fig. 3

Comparison of changes in ALCs, CD4, CD8 and CD4 plus CD8 cell counts pre- and after-treatment. ALCs, CD4, CD8, and CD4 plus CD8 counts by flow cytometry in good responders and poor responders in NSCLC patients receiving TKI treatment (Cohort A) (A, C, E, G) or receiving ICI (Cohort B) (B, D, F, H) are shown. Groups were compared by the Wilcoxon signed rank test. *P < 0.05 for statistical significance. Abbreviations: ALCs, absolute lymphocyte cells; ICI, immune checkpoint inhibitors

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us